GLP-1 and PCOS: Comparing Your Options

Key Takeaways

Network meta-analysis data suggest GLP-1 receptor agonists may outperform metformin and inositol on certain metabolic markers in women with PCOS, though head-to-head trial evidence is still limited.
Incretin-based therapies appear to influence ovarian function through multiple hormonal pathways, not just weight loss, according to recent molecular-science reviews.
A short-term randomized controlled trial found that combining tirzepatide with metformin produced greater improvements in weight and metabolic outcomes than either agent alone in overweight or obese women with PCOS.
Real-world data show rapidly rising use of incretin-based therapies in women with PCOS, often in younger patients with higher BMI and insulin resistance.
Current systematic review evidence on GLP-1 safety during preconception, pregnancy, and lactation remains limited, and most guidelines recommend discontinuing these medications before conception.

Why do metabolic and hormonal problems overlap in PCOS?

In PCOS, the metabolic and hormonal systems are locked in a feedback loop — each one making the other worse, so fixing just one side rarely solves the full picture. Understanding that loop is the key to understanding why PCOS is so hard to treat and why newer medications are generating real interest.

Here is how the cycle works, step by step:

Insulin resistance drives androgen excess. Insulin resistance means the body’s cells stop responding normally to insulin (the hormone that moves sugar from the blood into cells). The pancreas compensates by pumping out more insulin. Those high insulin levels signal the ovaries to produce more androgens — the group of hormones that includes testosterone. Metabolic-Hormonal Interplay describes this as a core mechanism linking metabolic dysfunction directly to the reproductive symptoms of PCOS.
Excess androgens worsen insulin resistance. The relationship runs both directions. Elevated androgens impair how muscle and fat tissue respond to insulin, which pushes insulin levels even higher, which drives androgen production even further. The loop tightens. Benefits of Incretin Therapy on Ovarian Function confirms that this bidirectional relationship is well established in the research literature.
Disrupted ovulation follows. High androgen levels interfere with the normal monthly process of egg maturation and release. Follicles (the small fluid-filled sacs in the ovaries that each contain an egg) start developing but stall before releasing. This is what produces the characteristic “polycystic” appearance on ultrasound and contributes to irregular or absent periods. Incretin-Based Anti-obesity Medications — The Evidence Map links this ovulatory disruption directly back to the underlying metabolic dysfunction.
Body weight amplifies everything. Excess body fat — particularly fat stored around the abdomen — deepens insulin resistance, which feeds back into higher insulin and higher androgens. Weight gain is both a consequence and a driver of the cycle. Comparative analysis of GLP-1 receptor agonists, metformin, and inositol (source) notes that metabolic and reproductive outcomes in PCOS are closely tied to body weight and insulin sensitivity.

The practical takeaway: because these systems are wired together, a treatment that improves insulin sensitivity can, in turn, lower androgen levels and support more regular ovulation — without targeting hormones directly. That is the biological rationale researchers are exploring when they study GLP-1 medications in people with PCOS.

This content is for general informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Never start, stop, or change any medication or treatment based on information you read here.

How do GLP-1 receptor agonists, metformin, and inositol compare for PCOS?

All three options can help manage PCOS, but a network meta-analysis found that GLP-1 receptor agonists produced the largest reductions in body weight and waist circumference compared with metformin and inositol, while metformin led on some hormonal markers and inositol showed meaningful insulin-related benefits with a gentler side-effect profile.

Here is what the evidence currently shows for each option:

GLP-1 receptor agonists (medications like semaglutide or liraglutide that mimic a gut hormone to regulate blood sugar and appetite)

The network meta-analysis ranked GLP-1 receptor agonists highest for reducing BMI and waist circumference across the treatments studied.
A systematic review and meta-analysis of randomized controlled trials found GLP-1 receptor agonists significantly lowered testosterone levels and improved menstrual regularity in women with PCOS.
A scientific literature review found evidence that GLP-1 receptor agonists may support ovarian function by reducing insulin resistance — a core driver of PCOS symptoms.
Nausea and digestive discomfort occur commonly, especially early in treatment.

Metformin (an oral diabetes medication used off-label for PCOS for decades)

The network meta-analysis found metformin performed well for improving androgen levels (male-type hormones that are often elevated in PCOS) and fasting insulin.
Metformin carries a long safety record and costs little, making it a common first choice for clinicians.
One randomized controlled trial tested combining tirzepatide (a dual GLP-1/GIP receptor agonist) with metformin and found the combination produced greater improvements in weight and hormonal markers than either treatment alone — suggesting these two work together rather than compete.

Inositol (a naturally occurring compound, often sold as a supplement, that supports insulin signaling)

The network meta-analysis found inositol improved insulin sensitivity and some hormonal markers, though its effects on weight were more modest than GLP-1 receptor agonists.
Inositol is generally well tolerated, which matters for people who struggle with the gastrointestinal side effects of the other two options.
Evidence for inositol comes from smaller studies, so the overall certainty is lower.

No single treatment wins across every outcome. The right choice depends on your specific symptoms, weight goals, and what your body tolerates — a conversation only you and your healthcare provider can have.

This content is for general informational purposes only and is not medical advice. It does not replace the guidance of a qualified healthcare professional. Always consult your doctor before starting, stopping, or changing any treatment.

Can GLP-1 medications directly affect ovarian function?

Yes — GLP-1 medications appear to have direct effects on ovarian function, not just indirect ones through weight loss. Researchers have found GLP-1 receptors (proteins that the medication “docks” onto to do its job) on ovarian tissue itself, which means these drugs may influence the ovaries through their own biological pathways, separate from any changes on the scale.

Here is what the current evidence shows:

GLP-1 receptors exist in reproductive tissue

Ovarian cells carry GLP-1 receptors. A 2025 literature review found that GLP-1 medications may act on those receptors to reduce inflammation inside the ovaries and lower levels of androgens — hormones like testosterone that, when elevated, can disrupt ovulation. This is a direct tissue-level effect, not a downstream result of eating less.

Hormonal changes researchers have observed

Studies in women with PCOS (polycystic ovary syndrome — a condition where hormone imbalance disrupts ovulation) show measurable shifts in reproductive hormones after GLP-1 treatment:

A systematic review and meta-analysis found that GLP-1 receptor agonists reduced testosterone levels and improved menstrual regularity in women with PCOS.
A network meta-analysis comparing GLP-1 drugs, metformin, and inositol found that GLP-1 medications produced meaningful improvements in androgen levels and metabolic markers in women with PCOS.
A randomized controlled trial using tirzepatide (a dual GLP-1/GIP receptor agonist) combined with metformin in women with PCOS showed improvements in ovarian function markers over a short treatment period.

What researchers do not yet know

Most studies so far have focused on women with PCOS, so it is unclear whether these ovarian effects apply equally to women without that diagnosis. A 2025 framework paper calls for more research specifically designed to separate the direct hormonal effects of GLP-1 medications from the hormonal changes that naturally follow weight loss — because both happen at once, and untangling them requires study designs that can isolate each variable independently.

The bottom line for you

These are early but real signals. GLP-1 medications are not fertility treatments, and no study guarantees a specific reproductive outcome for any individual. If ovarian health or fertility matters to your situation, bring these findings to a reproductive endocrinologist or OB-GYN who can look at your full picture.

This content is for general informational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decisions about your health or medications.

What does real-world use of incretin therapy in PCOS look like?

Most people with PCOS who use incretin therapy in real-world settings are doing so off-label — meaning the medications aren’t officially approved for PCOS, but doctors prescribe them based on growing evidence that they help with the metabolic and hormonal features of the condition.

A real-world cohort study from Poland tracked women with PCOS receiving incretin-based therapy through a private healthcare network and found that use grew sharply between 2019 and 2023. The women most likely to be prescribed these medications shared a specific profile:

Higher BMI — most had overweight or obesity at the time of prescribing
Insulin resistance — a condition where the body’s cells don’t respond well to insulin, forcing the pancreas to produce more
Metabolic syndrome features — such as elevated blood sugar, high triglycerides (a type of blood fat), or high blood pressure
Prior metformin use — many had already tried metformin, a common first-line PCOS medication

The Polish cohort study identified semaglutide as the most frequently prescribed agent, followed by liraglutide, with tirzepatide — a newer dual-action medication targeting both GLP-1 and GIP receptors — entering use more recently.

What do clinicians actually observe? A systematic review and meta-analysis of randomised controlled trials found that GLP-1 receptor agonists produced meaningful reductions in body weight, waist circumference, fasting insulin, and testosterone levels compared to placebo or lifestyle changes alone. Weight loss matters because excess weight drives many PCOS symptoms — reducing it can ease the hormonal imbalance at the root of irregular cycles and elevated androgens (male-type hormones that cause symptoms like excess hair growth and acne).

A network meta-analysis comparing GLP-1 medications, metformin, and inositol found that GLP-1 receptor agonists outperformed the other options on several metabolic measures, including BMI reduction and fasting insulin. Meaningful improvements. Not a cure.

One practical note on timing: a prospective randomised trial in Chinese women with PCOS tested tirzepatide combined with metformin over a short treatment window and found improvements in weight, hormone levels, and menstrual regularity — suggesting combination approaches are being actively studied, not just single-drug use.

Pregnancy planning adds a layer of complexity. A systematic review on safety during preconception and pregnancy found that current evidence is limited, and most guidelines recommend stopping these medications before attempting conception. Anyone with PCOS who is trying to conceive should discuss timing carefully with their care team.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

Is it safe to use GLP-1 medications before or during pregnancy?

Current evidence says GLP-1 medications should be stopped before trying to conceive and avoided throughout pregnancy and breastfeeding. No large, long-term human studies have confirmed these drugs are safe for a developing baby, and most prescribing guidelines reflect that gap.

Here is what the research currently shows:

Before pregnancy (preconception)

GLP-1 medications can support weight loss and improve metabolic health, which may benefit fertility — particularly for people with polycystic ovary syndrome (PCOS), a hormonal condition that affects ovulation. A 2025 systematic review found GLP-1 receptor agonists improved several metabolic markers in women with PCOS.
Losing weight before pregnancy is generally considered beneficial. The concern is timing: most clinical guidance recommends stopping GLP-1 medications at least two months before trying to conceive, because the drugs can stay active in your body for weeks after the last dose. A 2025 safety review confirmed this washout period is the current standard recommendation.
Fertility can return faster than expected once weight improves and cycles regulate. If you are sexually active and not using contraception, talk to your doctor before starting or continuing a GLP-1 medication.

During pregnancy

Stop. The 2025 safety review — which looked at maternal, fetal, and newborn outcomes across available studies — found the human data on GLP-1 use during pregnancy is too limited to establish safety. Animal studies have raised concerns about fetal development, though animal findings do not always translate directly to humans.
Accidental exposure during early pregnancy has been reported, since some people do not know they are pregnant right away. If this happens to you, contact your healthcare provider promptly rather than waiting. Early exposure does not automatically mean harm, but your care team needs to know.

During breastfeeding

Researchers do not yet know whether GLP-1 medications pass into breast milk or what effect that might have on a nursing infant. The 2025 safety review found no adequate human data on lactation, which means the safest current approach is to avoid these medications while breastfeeding.

The bottom line: GLP-1 medications show real promise for metabolic and reproductive health, and emerging research is actively exploring their role in reproductive medicine. Right now, the evidence base for use around pregnancy is thin. Plan ahead, talk openly with your doctor, and never stop or start a medication based on this guide alone.

This content is for general informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare professional who knows your individual health history.

What should women with PCOS ask their doctor about GLP-1 options?

Disclaimer: This content is for general informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare provider who knows your full medical history. Never start, stop, or change a medication based on information you read here.

If you have PCOS (polycystic ovary syndrome — a hormonal condition that affects ovulation, metabolism, and androgen levels) and you’re considering GLP-1 medications, bring a focused list of questions to your appointment. The right questions let your doctor tailor a plan to your specific situation, because PCOS affects weight, hormones, and fertility all at once — and GLP-1 drugs touch all three.

Questions worth asking:

“Is a GLP-1 right for my type of PCOS?” A systematic review and meta-analysis found that GLP-1 receptor agonists reduced body weight, fasting insulin, and testosterone levels in women with PCOS — but results varied across individuals. Your doctor can tell you whether your lab values and symptoms put you in a group likely to benefit.
“How does a GLP-1 compare to metformin or inositol for my goals?” These are common PCOS treatments. A network meta-analysis comparing GLP-1 drugs, metformin, and inositol found differences in how well each option improved weight, insulin resistance, and hormone levels — so the best choice depends on which outcomes matter most to you.
“Could combining a GLP-1 with metformin make sense for me?” Some research explores combination approaches. A randomized controlled trial in overweight and obese women with PCOS tested tirzepatide (a dual GLP-1/GIP receptor agonist — meaning it activates two hormone pathways instead of one) alongside metformin and found improvements in metabolic and hormonal markers over the treatment period.
“What might this medication do for my cycle or ovulation?” A scientific literature review found evidence that incretin-based therapies (the drug class GLP-1 medications belong to) may support ovarian function, though researchers note the evidence is still developing. Ask your doctor what realistic expectations look like for you.
“What if I want to get pregnant — now or later?” This question matters most. A systematic review of maternal and fetal outcomes found that safety data for GLP-1 medications during preconception, pregnancy, and breastfeeding remains limited. Your doctor needs to know your family planning timeline before prescribing.
“How will you monitor my hormones and metabolic markers over time?” Real-world data from a Polish cohort study showed that women with PCOS using incretin-based therapies had varied clinical profiles — which means ongoing monitoring matters, not just a one-time prescription.

Write your questions down before the visit. Short list. Honest answers.

FAQ

Are GLP-1 medications approved specifically for PCOS?

No GLP-1 receptor agonist currently carries a regulatory approval specifically for PCOS. They are approved for type 2 diabetes or chronic weight management in eligible adults. Research into their use for PCOS is ongoing, and any prescribing for this purpose is considered off-label. Always discuss this distinction with a qualified healthcare provider.

How do GLP-1 drugs compare with metformin for PCOS symptoms?

A 2025 network meta-analysis published in Frontiers in Endocrinology found that GLP-1 receptor agonists showed favorable effects on body weight, BMI, and certain metabolic markers compared with metformin and inositol in women with PCOS. However, the authors noted that the overall evidence base is still evolving and more large trials are needed before firm conclusions can be drawn.

Can GLP-1 medications improve menstrual regularity or fertility in PCOS?

Preclinical and early clinical data reviewed in the International Journal of Molecular Sciences suggest incretin-based therapies may positively influence ovarian function through hormonal pathways beyond weight reduction alone. However, this research is preliminary, and no GLP-1 drug is currently recommended as a fertility treatment. Speak with a reproductive endocrinologist or OB-GYN for personalized guidance.

Is tirzepatide different from standard GLP-1 medications for PCOS?

Tirzepatide targets both GLP-1 and GIP receptors (a dual agonist), which may produce different metabolic effects than single GLP-1 receptor agonists. A 2025 randomized controlled trial in overweight or obese Chinese women with PCOS found short-term combination therapy with tirzepatide and metformin led to greater improvements in weight and metabolic parameters than metformin alone. Longer-term and larger studies are still needed.

Should I stop a GLP-1 medication if I want to get pregnant?

A 2025 systematic review in Diabetes, Obesity & Metabolism found that safety data on GLP-1 and dual GLP-1/GIP receptor agonists during preconception, pregnancy, and lactation remain limited. Most current clinical guidance recommends discontinuing these medications before attempting conception. This is a critical conversation to have with your prescribing physician and OB-GYN well in advance of any planned pregnancy.

Who is most likely to be prescribed incretin therapy for PCOS in real-world practice?

A real-world cohort study from a Polish private healthcare network found that incretin-based therapy use in women with PCOS increased substantially between 2019 and 2023. Users tended to be younger women with higher BMI and more pronounced insulin resistance. This mirrors broader trends but does not mean every woman with PCOS is a candidate—individual clinical assessment is essential.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.